390 reports of this reaction
3.3% of all RAMELTEON reports
#4 most reported adverse reaction
MIDDLE INSOMNIA is the #4 most commonly reported adverse reaction for RAMELTEON, manufactured by Takeda Pharmaceuticals America, Inc.. There are 390 FDA adverse event reports linking RAMELTEON to MIDDLE INSOMNIA. This represents approximately 3.3% of all 11,977 adverse event reports for this drug.
Patients taking RAMELTEON who experience middle insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MIDDLE INSOMNIA is moderately reported among RAMELTEON users, representing a notable but not dominant share of adverse events.
In addition to middle insomnia, the following adverse reactions have been reported for RAMELTEON:
The following drugs have also been linked to middle insomnia in FDA adverse event reports:
MIDDLE INSOMNIA has been reported as an adverse event in 390 FDA reports for RAMELTEON. This does not prove causation, but indicates an association observed in post-market surveillance data.
MIDDLE INSOMNIA accounts for approximately 3.3% of all adverse event reports for RAMELTEON, making it a notable side effect.
If you experience middle insomnia while taking RAMELTEON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.